« Previous
Next »
Titles
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- How Medicaid and CHIP shield children from the rising costs of prescription drugs1
- Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices1
- Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters1
- No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending1
- Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates1